Design, synthesis, and In vitro antituberculosis activity of 2(5H)-Furanone derivatives.

IUBMB life, Volume: 68, Issue: 8
August 27, 2016
Andile H Ngwane AH, Jenny-Lee Panayides JL, Franck Chouteau F, Lubabalo Macingwana L, Albertus Viljoen A, Bienyameen Baker B, Eliya Madikane E, Carmen de Kock C, Lubbe Wiesner L, Kelly Chibale K, Christopher J Parkinson CJ, Edwin M Mmutlane EM, Paul van Helden P, Ian Wiid I

A series of 2(5H)-furanone-based compounds were synthesized from commercially available mucohalic acids. From the first-generation compounds, three showed inhibitory activity (10 µg/mL) of at least 35% against Mycobacterium smegmatis mc(2) 155 growth (Bioscreen C system). In screening the active first-generation compounds for growth inhibition against Mycobacterium tuberculosis H37Rv, the most active compound was identified with a minimum inhibitory concentration (MIC99 ) of 8.07 µg/mL (15.8 µM) using BACTEC 460 system. No cross-resistance was observed with some current first-line anti-TB drugs, since it similarly inhibited the growth of multidrug resistant (MDR) clinical isolates. The compound showed a good selectivity for mycobacteria since it did not inhibit the growth of selected Gram-positive and Gram-negative bacteria. It also showed synergistic activity with rifampicin (RIF) and additive activity with isoniazid (INH) and ethambutol (EMB). Additional time-kill studies showed that the compound is bacteriostatic to mycobacteria, but cytotoxic to the Chinese Hamster Ovarian (CHO) cell line. From a second generation library, two compounds showed improved anti-TB activity against M. tuberculosis H37Rv and decreased CHO cell cytotoxicity. The compounds exhibited MIC values of 2.62 µg/mL (5.6 µM) and 3.07 µg/mL (5.6 µM) respectively. The improved cytotoxicity against CHO cell line of the two compounds ranged from IC50  = 38.24 µg/mL to IC50  = 45.58 µg/mL when compared to the most active first-generation compound (IC50  = 1.82 µg/mL). The two second generation leads with selectivity indices (SI) of 14.64 and 14.85 respectively, warrant further development as anti-TB drug candidates. © 2016 IUBMB Life, 68(8):612-620, 2016.

Courtesy of the U.S. National Library of Medicine